Bacteriophage-derived endolysins as innovative antimicrobials against bovine mastitis-causing streptococci and staphylococci: a state-of-the-art review.

IF 1.9 2区 农林科学 Q2 VETERINARY SCIENCES
Niels Vander Elst
{"title":"Bacteriophage-derived endolysins as innovative antimicrobials against bovine mastitis-causing streptococci and staphylococci: a state-of-the-art review.","authors":"Niels Vander Elst","doi":"10.1186/s13028-024-00740-2","DOIUrl":null,"url":null,"abstract":"<p><p>Bacteriophage-encoded endolysins, peptidoglycan hydrolases breaking down the Gram-positive bacterial cell wall, represent a groundbreaking class of novel antimicrobials to revolutionize the veterinary medicine field. Wild-type endolysins exhibit a modular structure, consisting of enzymatically active and cell wall-binding domains, that enable genetic engineering strategies for the creation of chimeric fusion proteins or so-called 'engineered endolysins'. This biotechnological approach has yielded variants with modified lytic spectrums, introducing new possibilities in antimicrobial development. However, the discovery of highly similar endolysins by different groups has occasionally resulted in the assignment of different names that complicate a straightforward comparison. The aim of this review was to perform a homology-based comparison of the wild-type and engineered endolysins that have been characterized in the context of bovine mastitis-causing streptococci and staphylococci, grouping homologous endolysins with ≥ 95.0% protein sequence similarity. Literature is explored by homologous groups for the wild-type endolysins, followed by a chronological examination of engineered endolysins according to their year of publication. This review concludes that the wild-type endolysins encountered persistent challenges in raw milk and in vivo settings, causing a notable shift in the field towards the engineering of endolysins. Lead candidates that display robust lytic activity are nowadays selected from screening assays that are performed under these challenging conditions, often utilizing advanced high-throughput protein engineering methods. Overall, these recent advancements suggest that endolysins will integrate into the antibiotic arsenal over the next decade, thereby innovating antimicrobial treatment against bovine mastitis-causing streptococci and staphylococci.</p>","PeriodicalId":7181,"journal":{"name":"Acta Veterinaria Scandinavica","volume":"66 1","pages":"20"},"PeriodicalIF":1.9000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11106882/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Veterinaria Scandinavica","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1186/s13028-024-00740-2","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Bacteriophage-encoded endolysins, peptidoglycan hydrolases breaking down the Gram-positive bacterial cell wall, represent a groundbreaking class of novel antimicrobials to revolutionize the veterinary medicine field. Wild-type endolysins exhibit a modular structure, consisting of enzymatically active and cell wall-binding domains, that enable genetic engineering strategies for the creation of chimeric fusion proteins or so-called 'engineered endolysins'. This biotechnological approach has yielded variants with modified lytic spectrums, introducing new possibilities in antimicrobial development. However, the discovery of highly similar endolysins by different groups has occasionally resulted in the assignment of different names that complicate a straightforward comparison. The aim of this review was to perform a homology-based comparison of the wild-type and engineered endolysins that have been characterized in the context of bovine mastitis-causing streptococci and staphylococci, grouping homologous endolysins with ≥ 95.0% protein sequence similarity. Literature is explored by homologous groups for the wild-type endolysins, followed by a chronological examination of engineered endolysins according to their year of publication. This review concludes that the wild-type endolysins encountered persistent challenges in raw milk and in vivo settings, causing a notable shift in the field towards the engineering of endolysins. Lead candidates that display robust lytic activity are nowadays selected from screening assays that are performed under these challenging conditions, often utilizing advanced high-throughput protein engineering methods. Overall, these recent advancements suggest that endolysins will integrate into the antibiotic arsenal over the next decade, thereby innovating antimicrobial treatment against bovine mastitis-causing streptococci and staphylococci.

噬菌体衍生的内溶素作为创新抗菌剂,可抗击引起牛乳腺炎的链球菌和葡萄球菌:最新进展综述。
噬菌体编码的内溶酶是一种分解革兰氏阳性细菌细胞壁的肽聚糖水解酶,它是一类具有开创性的新型抗菌素,将在兽医领域掀起一场革命。野生型内溶素具有模块化结构,由酶活性域和细胞壁结合域组成,可通过基因工程策略制造嵌合融合蛋白或所谓的 "工程内溶素"。这种生物技术方法产生了具有改良溶菌谱的变体,为抗菌开发带来了新的可能性。然而,不同研究小组发现的高度相似的内溶菌素有时会被命名为不同的名称,从而使直接比较变得复杂。本综述的目的是以同源性为基础,比较在牛乳腺炎致病链球菌和葡萄球菌中发现的野生型和工程型内溶菌素,将蛋白质序列相似度≥ 95.0% 的同源内溶菌素分组。按照野生型内溶素的同源分组对文献进行了探讨,然后根据发表年份对工程内溶素进行了按时间顺序的审查。本综述的结论是,野生型内溶酶在生奶和体内环境中遇到了持续的挑战,导致该领域明显转向内溶酶的工程化。如今,人们通常利用先进的高通量蛋白质工程方法,在这些具有挑战性的条件下进行筛选试验,从中选出能显示强大溶菌活性的候选先导蛋白。总之,这些最新进展表明,内溶菌素将在未来十年内融入抗生素武器库,从而革新针对引起牛乳腺炎的链球菌和葡萄球菌的抗菌治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Veterinaria Scandinavica
Acta Veterinaria Scandinavica 农林科学-兽医学
CiteScore
3.60
自引率
0.00%
发文量
28
审稿时长
18-36 weeks
期刊介绍: Acta Veterinaria Scandinavica is an open access journal encompassing all aspects of veterinary research and medicine of domestic and wild animals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信